Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Published:2023-01-09 Issue:3 Volume:40 Page:1019-1030
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Fang Rui,Wang Suiqiong,Liu Yongqian,Xu Jun

Funder

Guangdong Medical Research Foundation

Guangdong Provincial Key Laboratory for Translational Cancer Research of Chinese Medicine, Guangzhou University of Chinese Medicine

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02402-z.pdf

Reference42 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.10.3322/caac.21660.

2. Abnet CC, Arnold M, Wei WQ. Epidemiology of Esophageal Squamous cell carcinoma. Gastroenterology. 2018;154:360–73. https://doi.org/10.1053/j.gastro.2017.08.023.10.1053/j.gastro.2017.08.023.

3. Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037–48. https://doi.org/10.1002/cac2.12197.10.1002/cac2.12197.

4. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134:783–91. https://doi.org/10.1097/CM9.0000000000001474.10.1097/CM9.0000000000001474.

5. Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25–43. https://doi.org/10.1007/s10388-018-0642-8.10.1007/s10388-018-0642-8.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China;Frontiers in Pharmacology;2024-05-15

2. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China;Expert Review of Pharmacoeconomics & Outcomes Research;2023-10-24

3. Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis;Cost Effectiveness and Resource Allocation;2023-09-13

4. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China;Frontiers in Immunology;2023-05-04

5. Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China;Expert Review of Pharmacoeconomics & Outcomes Research;2023-04-24